Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Gottlieb: 'Enormous Investment' Needed For New Flu Vaccine Technology
Volgen
March 09, 2018 A fundamental change in manufacturing would be needed for the United States to shift from “antiquated” egg-based flu vaccines to newer technologies like cell-based vaccines and recombinant DNA technology, which could pave the way toward a universal vaccine, government experts told lawmakers March 8. But investing in continuous manufacturing can help usher along this shift, FDA Commissioner Scott Gottlieb argued.www.fda.gov/NewsEvents/Newsroom/Press... - - - www.pharming.com/rnd/transgenic-produ... After the discovery of DNA and recombinant DNA techniques in the past decades it became possible to transfer genes between different organisms, such as plants and bacteria. Scientists discovered how to transfer mammalian genes into the genetic material of other animals, and breed transgenic animals with specific (mixed) characteristics. This new scientific approach of recombining genetic material from different biological sources became known as recombinant DNA technology and the animals generated with such technology as transgenic animals. - - Denk dat Pharming met hun TPT Platform nu bij velen op de radar komt te staan..
Zoveel meer dan Ruconest alleen!
..Continuous manufacturing holds great promise for both cell-based and recombinant vaccines, because supply could be more easily ramped up on short notice. dubbeltje begint langzaam aan te vallen..
Recombinant proteins Protein is an important component of all organisms. Each protein molecule consists of one or more polypeptide chains made of amino acids. There are 20 naturally occurring amino acids. Different series of amino acids are linked together by peptide bonds to form protein chains. Each protein has a unique sequence of amino acids. All the functions of proteins are dependent on their structures. Although information necessary for life is encoded by DNA or RNA, proteins perform a wide range of biological functions within organisms, including enzyme catalysis, defense, transport, support, motion, and regulation. According to their functions in the body, proteins can be divided into different categories, such as antibody, enzyme, messager, structural component, and transport/ storage protein. Given the important functions of proteins, proteins have been studied intensively and applied widely. In the past, the major way to obtain a specific protein was to isolate it from a natural source, which is generally inefficient and time-consuming. Recent advances in recombinant molecule biological techniques have made it possible to clone the DNA encoding a specific protein into an expression vector and express the protein in expression systems, such as bacteria, yeast, insect cells, and mammalian cells. Simply put, recombinant proteins are translated products of exogenous DNA in living cells. The production of recombinant proteins generally contains two major steps: molecule cloning and protein expression. Currently, recombinant protein production is one of the most powerful techniques used in life sciences. Recombinant proteins have wide applications in medicine, research, and biotechnology. 1. Medicine Therapeutic proteins provide important therapies for a variety of diseases, such as diabetes, cancer, infectious diseases, hemophilia, and anemia. Common therapeutic proteins include antibodies, FC fusion proteins, hormones, interleukins, enzymes, and anticoagulants. There is a growing demand for recombinant proteins for therapeutic applications. Human proteins obtained through genetic engineering play a key role in therapeutic medicines market. Currently, most of all recombinant therapeutic proteins are produced in mammalian cells because mammalian cells are capable of producing high-quality proteins similar to the naturally occurring ones. In addition, many approved recombinant therapeutic proteins are generated in Escherichia coli due to its well-characterized genetics, rapid growth, and high-yield production. Basically, therapeutic proteins can be classified into four groups. Group I: Therapeutic proteins with enzymatic or regulatory activity. These proteins replace a protein that is deficient or abnormal, up-regulate an existing pathway, or provide a new function or activity. Group II: Therapeutic proteins with special targeting activity. These proteins interfere with a molecule or organism or deliver other molecules. Group III: Therapeutic proteins as vaccines. These proteins help protect against foreign agents, autoimmune diseases, and cancer. Group IV: Therapeutic proteins as diagnostics. These proteins are generally purified and recombinant proteins. 2. Research Recombinant proteins help to elucidate the basic and fundamental principles of an organism. These molecules can be used to identify and locate the position of the protein encoded by a specific gene, and to uncover the function of other genes in various cellular activities such as cell signaling, metabolism, growth, replication and death, transcription, translation, and protein modification. Thus, recombinant proteins are frequently used in molecular biology, cell biology, biochemistry, structural and biophysical studies, and many other research fields. Recombinant proteins are useful tools in understanding protein-protein interactions. They have proven performance in several laboratory techniques, such as ELISA, Western Blot, and immunohistochemistry (IHC). Recombinant proteins can be used to develop enzymatic assays. When used in conjunction with a matched antibody pair, recombinant proteins can be used as standards such as ELISA standards. Moreover, recombinant proteins can be used as positive controls in Western blots. 3. Biotechnology Recombinant proteins are also used in industry, food production, agriculture, and bioengineering. For example, in breeding industry, enzymes can be added to animal feed to increase the nutritional value of feed ingredients, reduce feed and waste management costs, support animal gut health, enhance animal performance and improve the environment. Besides, lactic acid bacteria (LAB) have been used for a long time for the production of fermented foods, and recently, LAB has been engineered for the expression of recombinant proteins, which have wide applications such as improving human/animal digestion and nutrition.
..Recombinant proteins are useful tools in understanding protein-protein interactions. They have proven performance in several laboratory techniques, such as ELISA, Western Blot, and immunohistochemistry (IHC) Gert Jan Stam - Research Associate Analytical Development | LinkedIn Amsterdam en omgeving, Nederland - ?Research Associate Analytical Development - ?Pharming Group N.V. Research Associate Analytical Development at Pharming Group N.V. ... Specialties: Western blotting. ELISA RT-qPCR qPCR. Writing development reports. Writing standard procedures. Lab and supply management. Works council. GMP ... Developing, qualifying and trouble shooting assays (e.a. ELISA, Activity assays)
"The ultimate goal is to go to recombinant DNA technology" NIH Scientist Expects Universal Flu Vaccine in 5 Years But only version 1.0 -- a really effective product 'is many years out'www.medpagetoday.com/infectiousdiseas... ( TPT Platform...)
beeldscherm schreef op 5 april 2018 12:43 :
"The ultimate goal is to go to recombinant DNA technology"
NIH Scientist Expects Universal Flu Vaccine in 5 Years
But only version 1.0 -- a really effective product 'is many years out'
www.medpagetoday.com/infectiousdiseas... ( TPT Platform...)
Interessant stukje. Maar ook de reactie en de link van Vinu Arumugham daarop (Short sighted influenza control policy based on poorly designed vaccines will sicken more people). Voordat dit zover is volgen er vast nog heel wat discussies!
Sursum schreef op 5 april 2018 13:34 :
[...]
Interessant stukje. Maar ook de reactie en de link van Vinu Arumugham daarop (Short sighted influenza control policy based on poorly designed vaccines will sicken more people). Voordat dit zover is volgen er vast nog heel wat discussies!
klopt, maar er is "reuring" op het recombinant dna vlak/platformen...
FDA chief Gottlieb is building a regulatory speedway to accelerate gene therapy development. In a rallying cry for gene therapy, FDA Commissioner Scott Gottlieb says he’s determined to clear the pathway for drug developers in a move to accelerate the first wave of gene therapies pointed to the market. The first therapeutic area to benefit from new surrogate endpoints will be hemophilia, Gottlieb saidendpts.com/fda-chief-gottlieb-is-buil... - - rhFVIII (Factor VIII) Factor VIII (rhFVIII) Haemophilia A is an X chromosome linked hereditary disorder caused by defects in the Factor VIII (FVIII) gene that lead to lower levels of the functional FVIII protein. Lack of functional FVIII diminishes the body’s clotting ability, which in turn can lead to damaging or fatal bleeding episodes. Recombinant human Factor VIII is a natural human blood clotting factor and is in early-stage development for treatment of Haemophilia A. Haemophilia A is a hereditary disorder caused by defects in the Factor VIII gene. Lack of functional Factor VIII diminishes the body’s clotting ability, which in turn can lead to damaging- or fatal bleeding episodes. .. Under the terms of the agreement, Pharming will transfer the Pharming technology platform and manufacturing know- how to SIPI, such that joint global development for new products will take place at SIPI’s facilities in Shanghai and benefit from both the cost advantages of the Pharming platform and the competitive development and manufacturing costs structures at SIPI. The first projects to be jointly developed and manufactured at SIPI will be recombinant C1-inhibitor (conestat alfa) and Factor VIII.
Nu ga ik een Bolt-statement maken,op 21 june zal FDA baas Scott Gottlieb m.i ook aanwezig zijn (daarom ook in de US) als je onderstaand stuk eens diep op je laat inwerken/begrijpt..www.fda.gov/NewsEvents/Speeches/ucm60... alleen dit stukje al geeft te denken, The first therapeutic area we’ll focus on is hemophilia, where factor production may be sufficient in some cases as a surrogate measure of benefit where a gene therapy product can potentially normalize factor production. In these settings, the demonstration of a reduction in bleeding rates could be confirmed post approval, as we continue to study a product’s long-term safety and durability. The other guidance documents that we’ll release will deal with specific manufacturing and clinical issues related to gene therapy products. By providing clarity to developers on manufacturing parameters, safety measures, and the pathway toward clinical development, the FDA hopes to foster even greater innovative development in this field. Once these draft guidance documents are released, we’ll look forward to your comments on them. We value the benefit of input from informed stakeholders such as the Alliance for Regenerative Medicine. The challenges we see, related to gene therapy products, are the sort of questions that we can help resolve by working together. Though gene therapies have the potential to address both common and rare diseases, currently they hold out tremendous hope in our country -- especially for those with the more than 7,000 different rare diseases. The challenges in developing products for such rare diseases that may affect anywhere from less than a hundred people -- to tens of thousands of individuals -- are apparent to all of us at the FDA. shoot me!
cellculturedish.com/2018/03/cell-ther... Cell Therapy Manufacturing – Opportunities and Challenges luister naar de audio vanaf min.3 en dan vanaf 15.40 over de verandering van "cocktail making platforms" naar na mijn mening, Pharmings platform die infeite nog niet bestaan, hij benoemt het ff anders,
beeldscherm schreef op 3 juni 2018 14:13 :
cellculturedish.com/2018/03/cell-ther... Cell Therapy Manufacturing – Opportunities and Challenges
luister naar de audio vanaf min.3 en dan vanaf 15.40
over de verandering van "cocktail making platforms" naar na mijn mening, Pharmings platform die infeite nog niet bestaan, hij benoemt het ff anders,
Dank je! Ik was al wel overtuigd van de waarde van het transgene platform. Dat is precies de reden waarom ik LT zit. Ik hoop idd. ook dat dat kwartje ook bij anderen begint te vallen ;-)
In 2011 was er al belangstelling voor het platform.www.rtlnieuws.nl/economie/pharming-me...
LT belegger schreef op 3 juni 2018 14:39 :
[...]
Dank je! Ik was al wel overtuigd van de waarde van het transgene platform. Dat is precies de reden waarom ik LT zit. Ik hoop idd. ook dat dat kwartje ook bij anderen begint te vallen ;-)
Ceo Sijmen de Vries van Pharming: Volgens hem kan een bedrijf als Pharming zelfstandig veel meer maken en betekenen voor de ontwikkeling van nieuwe geneesmiddelen. En hoe meer- waarde je creëert.... dat doen we liever zelf. Pharming is deze woorden ook aan omzetten in daden en is LT gewoon een prima beslissing.
U.S. officials removing special rules for gene therapy experiments.www.ctvnews.ca/health/u-s-officials-r... ..It’s time to let the FDA review gene therapy proposals on its own without duplicating regulatory efforts, the NIH’s director, Dr. Francis Collins, and FDA chief Dr. Scott Gottlieb wrote Wednesday in the New England Journal of Medicine. The proposed changes will go into effect after a public comment period.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
AIRBUS
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia Oyj
Nokia OYJ
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)